DUBLIN–(BUSINESS WIRE)–Sep 19, 2018–The “Innovations in Drug Delivery, Cancer Immunotherapies, Biomarker Identification, and Gene Therapy for Preventing Vision Loss” report has been added to ResearchAndMarkets.com‘s offering.

This Genetic Technology TOE depicts life sciences trends across drug delivery platforms, cancer immunotherapies, biomarker identification, and gene therapy.

Among the therapeutic areas in focus, age-related macular degeneration (AMD), aggressive childhood cancers, and bladder cancer, are of note.

Clinical trial analysis of recombinant drugs for different forms of cancer is also presented.

Key Topics Covered

Advancements in Mode of Drug Delivery for Age-related Macular DegenerationImmunotherapy Developments for Aggressive Childhood CancersNovel Biomarkers for p53-like Subtype of Bladder CancerNovel Gene Therapy Construct that Halts Vision LossClinical Trial Analysis of Recombinant Drugs for Different Forms of CancerKey Contacts

For more information about this report visit https://www.researchandmarkets.com/research/3bvvvg/2018—innovations?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180919005794/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Genomics,Drug Delivery,Oncology Drugs,Biomarkers

KEYWORD:

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS GENETICS ONCOLOGY OPTICAL PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/19/2018 03:57 PM/DISC: 09/19/2018 03:57 PM

http://www.businesswire.com/news/home/20180919005794/en

Copyright Business Wire 2018.



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *